Navigation Links
NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
Date:4/29/2009

1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the size, scope and growth of potential markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' product candidates and its plans with regard to seeking potential development partners for its early stage product pipeline. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret pr
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
2. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
3. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
4. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. NeurogesX Reports Third Quarter 2008 Results
6. NeurogesX to Report Third Quarter 2008 Financial Results
7. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
8. NeurogesX Responds to EMEAs Day 120 Questions
9. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
10. NeurogesX Reports Second Quarter 2008 Results
11. NeurogesX to Report Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 As the R&D ... push within the industry to deliver better products, ... and pharma companies often means turning big ideas ... developed in collaboration with Sensidose AB and Recipharm, ... bring products to market sooner. The partnership resulted ...
(Date:5/21/2013)... 2013 Emerson Resources Inc. , ... Charles Signorino, the Company’s Chief Executive Officer and Chairman ... 32 years of service. As part of Emerson Resources’ ... has been named as Dr. Signorino’s successor. , ... industry, having made a significant contribution to the field ...
(Date:5/21/2013)... Md. , May 21, 2013  Synthetic Biologics, Inc. ... prevention and treatment of serious infectious diseases, announced today that ... the 2 nd Annual Marcum LLP MicroCap Conference on ... at the Grand Hyatt Hotel. Mr. Riley is ... A live webcast of Synthetic Biologics, presentation can be accessed ...
(Date:5/21/2013)... NY (PRWEB) May 21, 2013 Bed bugs ... according to My Cleaning Products, many turn to chemical-based pesticides ... of the health and environmental risks those solutions present, the ... with Bed Bug Bully instead. , According to My ... bugs as they used to be. It shared that the ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... ATHENS, Ohio Scientists have used new optical technologies ... principle usually would prohibit, according to a study published ... conducted experiments with high-powered lasers and quantum dots artificial ... devices for quantum communication and computing to learn ...
... MISSISSAUGA, ON, Jan. 16 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: ... operations for the,fiscal year ended November 30, 2007. ... unless otherwise noted., At November 30, 2007, ... with $30.4 million at November 30, 2006. The ...
... China, Jan. 16 /Xinhua-PRNewswire/ -- WuXi PharmaTech ... outsourcing services is,proud to announce today that ... Li is named as one of the ... Entrepreneur China edition., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ...
Cached Biology Technology:Scientists discover new method of observing interactions in nanoscale systems 2Vasogen Announces 2007 Year-End Results 2Vasogen Announces 2007 Year-End Results 3Vasogen Announces 2007 Year-End Results 4Vasogen Announces 2007 Year-End Results 5Vasogen Announces 2007 Year-End Results 6Vasogen Announces 2007 Year-End Results 7Vasogen Announces 2007 Year-End Results 8Vasogen Announces 2007 Year-End Results 9Vasogen Announces 2007 Year-End Results 10Vasogen Announces 2007 Year-End Results 11WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs 2WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs 3
(Date:5/22/2013)... in fuel cell powered buses, including a team ... electrode degradation processes and bus membrane durability. , ... degradation stressors in the operating cycle of the ... of the study, led by SFU graduate student ... study at Burnaby-based Ballard Power Systems and funded ...
(Date:5/22/2013)... major new effort to educate the public and decision ... clean water that looms ahead in the 21st century. ... current edition of Chemical & Engineering News , ... the world,s largest scientific society. , Bassam Z. Shakhashiri, ... Ph.D., explain that shortages of reliable supplies of fresh ...
(Date:5/22/2013)... to genetic engineering drastically reduces the time and ... the workhorses of biotechnology, scientists are reporting. Published ... the method paves the way for more rapid ... cleanup and other activities. , Keith Shearwin and ... of the genetic material DNA into a bacterium,s ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... Hypnosis can induce "synesthetic" experiences where one sense ... average brain, according to a new study in the ... the Association for Psychological Society. The findings ... do not necessarily have extra connections in their brain; ...
... infection is not a positive experience. However, by ... melanogaster with a Salmonella strain known for ... of Life Sciences at Arizona State University have ... with broad implications for understanding embryonic development, ...
... scientists say that a recent scientific study of a ... second, potentially more significant source of radon exposure for ... ore in the production arearesulted in relatively high levels ... More than half (56 percent) of the workers ...
Cached Biology News:Ben-Gurion University of the Negev researchers help find that hypnosis can induce synesthesia 2Making flies sick reveals new role for growth factors in immunity 2Making flies sick reveals new role for growth factors in immunity 3Making flies sick reveals new role for growth factors in immunity 4Major source of radon exposure overlooked at former Ohio uranium-processing plant 2Major source of radon exposure overlooked at former Ohio uranium-processing plant 3Major source of radon exposure overlooked at former Ohio uranium-processing plant 4
Request Info...
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: